Aura Biosciences (AURA) Equity Average (2020 - 2026)

Aura Biosciences has reported Equity Average for 7 years, with the latest figure at $122.1 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 12.78% year-over-year to $122.1 million; the trailing twelve-month figure through Mar 2026 stood at $122.1 million (down 12.78% YoY), and the FY2025 full-year result was $144.4 million, down 23.54% from the prior year.
• Equity Average for Q1 2026 stood at $122.1 million, down from $146.8 million in the prior quarter.
• The five-year high for Equity Average was $217.3 million in Q1 2024, with the low at $122.1 million in Q3 2022.
• Historically, Equity Average has averaged $162.2 million across 5 years, with a median of $159.1 million in 2023.
• Annual changes were most pronounced in 2022 — Equity Average surged 1358.39% — and 2025, when it slumped 35.59%.
• Aura Biosciences' Equity Average stood at $155.3 million in 2022, then gained by 21.55% to $188.8 million in 2023, then fell by 13.49% to $163.3 million in 2024, then slipped by 10.12% to $146.8 million in 2025, then slipped by 16.83% to $122.1 million in 2026.
• The last three Equity Average figures came in at $122.1 million (Q1 2026), $146.8 million (Q4 2025), and $165.6 million (Q3 2025), per Business Quant data.